This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2017
  • /
  • 01
  • /
  • U.S.District Court grants injunction to Amgen to p...
Drug news

U.S.District Court grants injunction to Amgen to prevent Sanofi + Regeneron marketing Praluent (alirocumab) in the US due to patent infringement.

Read time: 1 mins
Last updated:28th Jun 2017
Published:8th Jan 2017
Source: Pharmawand

Sanofi and Regeneron Pharmaceuticals, Inc. announced that they will appeal the injunction granted by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent (alirocumab) in the U.S. during the term of two Amgen patents. The companies believe Amgen’s asserted patent claims are invalid and will also appeal a prior jury verdict upholding the validity of those patents. The court has delayed imposition of the injunction for 30 days to allow Sanofi and Regeneron to file a motion for a suspension (stay) of this injunction during the appeal process. Praluent continues to be available to patients at this time.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.